Restarting Vyvanse After a Two-Week Break
Yes, you can restart lisdexamfetamine (Vyvanse) at 50 mg daily after a two-week break without re-titration. The FDA label and clinical trial data demonstrate that patients can be maintained on their established therapeutic dose without requiring dose escalation after brief treatment interruptions 1.
Rationale for Direct Restart
The pharmacokinetic profile of lisdexamfetamine supports immediate resumption at the previous therapeutic dose:
No tolerance development in two weeks: Lisdexamfetamine is a prodrug that requires enzymatic conversion by red blood cells to active dextroamphetamine. This mechanism remains unchanged after brief discontinuation 1.
Clinical trial precedent: Studies demonstrate patients can be randomized to their optimized doses after washout periods without safety concerns. In crossover trials, patients switched between active treatment and placebo on a weekly basis without adverse events requiring dose re-titration 1.
Rapid elimination: Approximately 96% of the drug is eliminated within 120 hours (5 days), meaning the patient has been completely drug-free for over a week 1. There is no accumulation or withdrawal syndrome requiring gradual re-introduction.
Key Safety Considerations
Monitor cardiovascular parameters at the restart visit:
- Pulse rate (watch for increases >7 bpm from baseline)
- Blood pressure (systolic and diastolic)
- Document any interval cardiac symptoms 2
Assess for interval changes that would contraindicate restart:
- New cardiovascular disease or uncontrolled hypertension
- Development of psychiatric symptoms (psychosis, mania, suicidal ideation)
- New substance use concerns, particularly stimulant misuse 3
Common Pitfalls to Avoid
Do not re-titrate from 30 mg. The FDA label specifies that initial titration (starting at 30 mg and increasing by 20 mg weekly) is only required for treatment-naïve patients 1. Your patient has already demonstrated tolerability at 50 mg for several months.
Do not confuse this with long-term discontinuation. While the evidence provided doesn't specify an exact timeframe, two weeks is a brief interruption. The patient's previous therapeutic response and tolerability at 50 mg remain valid.
Anticipate transient side effects in the first few days: Even at the same dose, patients may experience mild appetite suppression, insomnia, or headache upon restart, similar to initial treatment. These typically resolve within days and do not require dose adjustment 2.
Documentation
Document the reason for the two-week gap and confirm:
- Previous dose (50 mg) and duration of treatment
- Reason for discontinuation
- Absence of new contraindications
- Patient understanding of expected effects upon restart
The maintenance phase monitoring schedule applies immediately: monthly follow-up is appropriate once symptoms are stable 4.